I was just talking about this so I’ll share it here. These trials are all done. I listed the pooled data that Cytodyn put together that will be used for the upcoming data on mTNBC in May.

A small group lived beyond 36 months as per the last PR and are now cancer free. I hope that this data, even though small, will give us the green light to apply for BTD again. Depending on the survival numbers, this could be a big deal.

Here’s the breakdown down of all 28 treated for mTNBC. Figured it would be a good reference since it’s been awhile since this was discussed. The data and publications should be available mid May.

• All patients were listed as mTNBC
• n=16 were from Compassionate Use
• n=10 were from mTNBC trial
. n=2 were from Basket trial
• Patients received 21 dose of Leronlimab (range 1 - 33 doses)
• Doses ranged from 350mg - 700mg
• 4 patients had dose escalation per study protocol
• Average age was 52 (range 33 - 75)

This data was as reported by August 15, 2021.

I can’t recall how many survivors were left on the last update. I thought it was shared at some point back in 2021. The CTCs significantly decreased with leronlimab. The potential here is pretty incredible the more you dig into it.